Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
We had a great video from the Croda project lead lady that confirmed we are at the end of the project at the last invest meets presentation about a month or so ago, that's the first time we've heard directly from Croda. We also had a video from the chap at Dermatonics which talked about the Modi group opportunity, I would say that is all very positive. I would imagine SA is flat out trying to clear out the remainder of the convertible loan facility. That would be the best news we could get in the near term. Until then, IMHO the SP will not budge as the market fears the remaining conversions dragging the price down. That's all that's stopping me piling in. In the meantime a little top up here and there to bring my average down is all I'm comfortable with.
Acne news should be first to come this month, just not sure when.........
GLA
If by news you mean more conversion notices then possibly :) .... Im holding here but just zero faith in Manpr*ck and stuart has sector knowledge/expertise but incredibly poor CEO in many regards - I'd rather he surround himself with stronger advisors/people with better corp experience than Manpr*ck (and believe me they can be hired at the same or likely lower cost)
A few big deals today, does that mean we might get some early news from the main man? We can but hope that there is some positivity to come given how long we have been waiting for some positive news. Fingers crossed, GLA.
Tomorrow is the last day of April, a month where absolutely nothing has happened for Skin as SA indicated when he advised that the Acne results wouldn't be released to the market until May. An 8 weeks study which has lasted 4 months, given that 5 weeks info was released in February. Still, happy to give him the benefit of the doubt as we are now about to hear some news in the coming days/weeks. How long it takes them to write up their report on the study and what happens next should be interesting. I don't expect anything this week, next week maybe, hopefully. Will it be positive news or a flop?
I'm hopeful at the moment but the longer we have to wait for news......
GLA
So are the trades at 9.1475p
The 26189 trade is a buy, and not a sell.
Mrvivo, New profile, one post, looks like Mr Sheedy trying to worm his way back in. Do us all a favour and do some homework.
I agree wholeheartedly.
FD/CEO and BoD reviewed finance and must have known the risks and factored it in and agreed to go ahead.
DYOR on skills that allowed this. It speaks for itself. I have lost all confidence and the pay haircut is insulting based on loss of value that has occurred.
SBTX roles: CEO, FD, a Capital market advisor apparently, non-executive chair, two Non executives dir. Ability to perform any governance has been shown lacking. One non exec has background in brewing, one has background in cell therapy. No clinical studies to drive uptake with 550 customers after two and a half years and marketing that seems dominated by company recommending itself. Skills and relevance must now be questioned and corrected with urgency to change the trajectory.
Head of formulation, Financial controller, Customer service manager. Others?
Dermatonics roles: founder/advisor (who sold the business so he could retire so earn questions here given extra £££ we are paying in 24/25 ), Financial controller, Manager, sales consultant, Others????
light on experience so obvious why deadlines seem unimportant and are essentially never hit.
PG, I think it's World Products. It's not global, but UK, Europe and USA via Amazon.
I think you are referring to the consumer study for Acne. It is due at any time, but it needs to be written. I am more interested in Dermatonocs sales, UMG forecasts, and Croda launch/forward sales circa June, from memory. These news items are directly related to money now, not months later. These will drive a massive re-rate.
CB resolution would also drive a re-rate for obvious reasons, but I think most of us are aware of why.
Elrico, haven't they signed up a global sales team for amazon global sales? Have we past another deadline for news update for axis?
I agree Leapfroggy Bekker is definitely a weak link and has done nothing in the 2 years since she was hired. I didn’t understand her appointment in the first place. She has no relevant transferable experience and is an unnecessary waste of a seat at the table. Needs to be replaced with someone who can deliver and has sector experience.
Leepfroggy, I suspect there will be a coming together of minds to work out the best strategy in the future with the Dermatonics staff, who have had some success with their own sales/marketing team. This must be one synergy that some people have overlooked.
About time we had a new set of Directors to reflect the need to take our products to the market. Now we have an agency to develop our online presence, I fail to see why we need Danielle Bekker whose CV looks pretty lightweight and failed to create sales for Axisbiotix.
Good results from l'Oreal today and of particular note "All Divisions grew with stellar performances from the Consumer Products and Dermatological Beauty Divisions" so the Consumer appetite is certainly there for quality ingredients and products.
https://www.loreal-finance.com/eng/news-release/first-quarter-2024-sales
Boardroom changes???????
Never known it so quiet, hopefully acne study out soon.
It’s ironic that I subscribed to this web site recently and after reading this article and considering opinion on the future of UK stocks (which pension funds have stopped investing in) and the future for Aim (down 50% since 2021) and the near impossibility of funding I have sold up most of my Aim holdings. When the overall direction is overwhelmingly down, it doesn’t make sense to me to continue trading on Aim. That there have only been 10 AIM IPOs so far this year tells me the market is broken. It costs around £200k in RNS etc just to stay on Aim. I’m still holding on SBTX (but not adding) and URAH (main market and recently raised twice at around the SP).
It is not specific to SBTX, but it provides details of the board's predicament. Some people may not appreciate it, but they will!
OPEN SOURCE
https://open.substack.com/pub/smallcompanychampion/p/londons-capital-conundrum?r=398wvs&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true
Hello Martinu
I am not well versed in such matters either but the RNS implies a direct relationship between macquarie and the purchasers, I assume they agree a price between them.
'Long term shareholders, including Tyndall Investement Management who have invested in the Company since IPO, have agreed to purchase the shares directly from Macquarie Bank.'
Yes Madabout, there is something to be said for the facility to be almost halfway done in this timeframe. I’m pleased about it. I’d like to know how SA feels about it and if it influences his next moves on removing the company from the CLN which they have acknowledged the market reacted badly to. Well, I think we know it will have influenced things in that it will make it easier for SA to deal out of the agreement. I’ll look forward to asking about it at the next IMC presentation.
Why would Macquarie sell at the conversion price? They want an upside surely? The very large trade the other day was at 9p so they would have made 2.5p per share margin and Tyndall get a large block of shares to add to their already significant holding below market price. The good news is that the newly released shares now sit in long term holders hands and the facility is almost halfway done in under 3 months.
Nick, as someone who is not well versed in such matters, I was wondering about such questions. Are Macq able to transfer direct to, eg Tyndall ? (Recall, Tyndall weren't the only participator). If this direct transfer is possible, would Tyndall and others have wanted a price closer to 6.5p.
I know my input will not be appreciated as I am apparently a troll. If macquarie exercise their options and sell to Tyndall my understanding is they can do that 'off market' is that correct? If so the buys/sells are not anything to do with Macquarie. Also if all the large transactions are Macquarie selling to Tyndall why not the same price?
IMHO,
The 12 preferential clients would have formulated the lysate into their brands and will have produced the marketing and advertising for when Croda launches the ingredient. These cosmetic giants will compete to be first to market. We then can monitor the reception of the product, which I believe will be marketed very rapidly.